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ABSTRACT
Chaperone dependency of cancer cells is an emerging trait that relates to the 
need of transformed cells to cope with the various stresses associated with the 
malignant state. URI1 (unconventional prefoldin RPB5 interactor 1) encodes a 
member of the prefoldin (PFD) family of molecular chaperones that acts as part of a 
heterohexameric PFD complex, the URI1 complex (URI1C), to promote assembly of 
multiprotein complexes involved in cell signaling and transcription processes. Here, 
we report that human colorectal cancer (CRCs) cell lines demonstrate differential 
dependency on URI1 and on the URI1 partner PFD STAP1 for survival, suggesting 
that this differential vulnerability of CRC cells is directly linked to URI1C chaperone 
function. Interestingly, in URI1-dependent CRC cells, URI1 deficiency is associated 
with non-genotoxic p53 activation and p53-dependent apoptosis. URI1-independent 
CRC cells do not exhibit such effects even in the context of wildtype p53. Lastly, in 
tumor xenografts, the conditional depletion of URI1 in URI1-dependent CRC cells was, 
after tumor establishment, associated with severe inhibition of subsequent tumor 
growth and activation of p53 target genes. Thus, a subset of CRC cells has acquired 
a dependency on the URI1 chaperone system for survival, providing an example of 
‘non-oncogene addiction’ and vulnerability for therapeutic targeting.
INTRODUCTION
The progression of normal towards malignant 
tumor cells is invariably associated with increased 
proteotoxic stress perpetrated, in part, by the acquisition 
of genomic abnormalities (e.g. mutations, aneuploidy, 
copy-number variations) and the tumor microenvironment 
(e.g. hypoxia, acidosis). The consequent imbalances 
in protein expression, production of mutant proteins 
and assembly of multiprotein complexes with altered 
molecular composition and subunit stoichiometry creates 
a high demand for molecular chaperone systems to guard 
against protein misfolding, aggregation and promiscuous 
and dysfunctional protein-protein interactions [1]. 
Accordingly, tumor cells exhibit increased dependency 
on molecular chaperone systems for their survival, an 
observation particularly well illustrated in the case of the 
heat-shock protein (HSP) families HSP90 and HSP70 
that are frequently overexpressed in human cancer and 
display marked anti-apoptotic activities and potent tumor-
promoting activities [2].
Prefoldins (PFDs) are members of an evolutionary 
conserved protein family of molecular chaperones with 
roles in de novo protein folding, inhibition of protein 
aggregate formation and assembly of multiprotein 
complexes involved in cell signaling and transcription 
processes [3]. The human genome encodes nine PFDs 
with N- and C-terminal α-helical coiled-coil structures 
connected by either one (β-class PFDs) or two (α-class 
PFDs) β-hairpins that can assemble with an α2β4 subunit 
stoichiometry into hetero-hexameric complexes [4]. Two 
major hexameric PFD complexes have been described 
to date in mammalian cells and include the ‘prefoldin/
GimC’ complex and the prefoldin-like ‘unconventional 
prefoldin RPB5-interactor (URI)1’ complex (URI1C) [5-
7]. Prefoldin/GimC is composed of PFDs 1 to 6. URI1C 
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encompasses the α-class PFDs URI1 and STAP1 (SKP2-
associated alpha PFD [5]; also referred to as UXT [8] 
or ART-27 [9]) and the β-class PFDs PFD2, PFD6 and 
PFD4-related (PFD4r [5]; also referred to as p53 and DNA 
damage-regulated 1 [PDRG1] [10]). It is assumed that in 
the URI1C one member of the β-class PFDs is present in 
two copies to satisfy a α2β4 subunit stoichiometry. Both 
prefoldin/GimC and URI1C subunits cooperate with other 
chaperones and/or co-chaperones including HSP90, 
HSP70 and HSP40, R2TP (Rvb1, Rvb2, Tah1, Pih1) and 
TRiC/CCT to help cells to cope with various stresses and 
in this manner to support the normal operation of a broad 
spectrum of cellular activities [11-14].
URI1 is referred to as an unconventional PFD 
since it is the only member of this family that possesses, 
besides all structural features of an α-class PFD, an 
about 200 amino acid long C-terminal extension [5]. 
This segment harbours specific binding sites for RPB5/
POLR2E (polymerase RNA II DNA-directed polypeptide 
E) [15] and PP1γ (protein phosphatase 1, catalytic subunit, 
gamma isoform) [16] to mediate the assembly of RNA 
polymerases and to increase S6K1 survival signaling, 
respectively. Amplification and/or deregulated expression 
of URI1 has been observed in various cancer contexts 
including ovarian and hepatocellular carcinoma and 
multiple myeloma, supporting the view that URI1 may 
act as a multifaceted modifier of cancer cell proliferation 
and survival [17-22].
Given the structural and functional relationships 
of URI1 with molecular chaperones, we hypothesized 
that in this function, URI1 may help cancer cells to cope 
with the stress associated with oncogenic transformation. 
Accordingly, certain cancer cells may have evolved a 
specific dependency on the URI1 chaperone system 
for their survival. Here, we investigated whether such 
vulnerabilities exist in the context of colorectal cancer 
(CRC) cells.
RESULTS
Differential requirement of URI1 function for 
survival of CRC cell lines
To assess whether URI1 is amplified or not in human 
CRC cell lines, we analyzed copy number variation (CNV) 
data of URI1 in the cancer cell line encyclopedia (CCLE, 
http://www.broadinstitute.org/ccle/home). This analysis 
revealed a lack of amplification of the URI1 locus in CRC 
cell lines (Supplementary Table S1). This observation 
also extended to human CRC samples represented in The 
Cancer Genome Atlas of the TCGA Research Network 
(GISTIC results accessed through Tumorscape; http://
www.broadinstitute.org/tumorscape) (Supplementary Table 
S2). A similar analysis performed for the gene encoding 
STAP1, the α-class PFD partner of URI1, revealed also no 
evidence of amplification in human CRC (data not shown).
In the absence of any indication of URI1 
amplification in human CRC, we assessed the effects of 
URI1 depletion on cell survival in a panel of 14 CRC cell 
lines with different mutational background and varying 
levels of URI1 protein and mRNA expression (Figure 1A 
and 1B). This cell line panel was infected independently 
with two specific shRNAs targeting URI1 [shURI1(1) 
and shURI1(2)] and the extent of apoptosis quantified by 
flow cytometry using combined Annexin V / propidium-
iodide (PI) staining. Figure 1C illustrates the differential 
effects of URI1 depletion in four CRC cell lines. While 
RKO(mut) and VACO(wt) were highly dependent on 
URI1 function for their survival, HCT15 and Lovo were 
not. URI1 depletion also reduced colony formation of 
RKO(mut) and VACO(wt), but not of HCT15 and Lovo 
cells (Figure 1D). Analysis of the apoptotic responses to 
URI1 depletion in 10 additional CRC cell lines revealed 
that some cell lines display no or low, some moderate 
and yet other high dependency on URI1 for their survival 
(Supplementary Figure S1A). Thereafter, we refer to these 
distinct groups as URI1-independent (red bars) and URI1-
dependent (green bars) CRC cell lines (Figure 1E). To 
corroborate that this differential vulnerability of certain 
CRC cells is not the result of insufficient downregulation 
of URI1 in URI1-independent cells, we combined shRNAs 
and siRNAs targeting URI1. The latter combination was 
highly efficient in depleting URI1 in the URI-independent 
cell line Co115 as evidenced by immunoblotting 
(Supplementary Figure S1C). Importantly, this treatment 
did not significantly increase cell death (Supplementary 
Figure S1B), indicating that URI1-dependency is not the 
result of an inefficient depletion but rather an intrinsic 
property of certain CRC cells.
The Achilles data portal catalogs results from 
genome-scale interrogation of gene function using pooled 
lentiviral shRNAs across hundreds of cancer cell lines 
(http://www.broadinstitute.org/achilles) [23]. A search for 
PFD genes and their impact on CRC cell lines revealed 
data only for URI1 and PFD1 in 20 CRC cells lines, of 
which 8 were also in our cell line panel. Intriguingly, 
across these 20 CRC cell lines, some cell lines 
demonstrated no or low, some moderate and yet other high 
dependency on URI1 for their survival (Figure 1F) thus 
corroborating our findings of the existence of a differential 
requirement for URI1 for CRC cell survival. The results 
of knockdowns of PFD1 by two distinct shRNA pools 
provided in the Achilles data portal show pattern of 
dependency for survival distinct to URI1. We note that 
ample biochemical evidence suggest that PFD1 is not part 
of the URI1 complex [4-7]. Data on other components 
of the URI1C are currently not contained in the Achilles 
database. To extend this analysis, we asked next whether 
the URI1 survival dependency pattern identified correlates 
with genes that represent signaling network components to 
which URI1 has been previously functionally connected. 
This includes the PI3K-mTORC-S6K pathway [16] and 
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Figure 1: Differential requirement of URI1 function for the survival of CRC cell lines. A. Representative immunoblot 
showing URI1 expression in a panel of 14 CRC cell lines (n=2). β-actin served as loading control. B. mRNA expression of URI1 across 
the same panel of CRC cell lines as in (A). by quantitative RT-PCR (qPCR). Data were normalized to TBP and GAPDH, and Colo205 
URI1 mRNA levels were used as arbitrary reference sample (set to 1.0). Data are shown as means of three biological replicates, ± SD. 
C. Left panel: Immunoblots for URI1 in indicated CRC cell lines after targeting URI1 with two different shRNAs or a control shRNA. 
Total ERK1/2 served as loading control. Right panel: Representative apoptosis measurements of cells described in the left panel using 
Annexin V-GFP and propidium iodide (PI) double-staining (n=3). D. Representative clonogenic assays of cells described in (C; left panel) 
(n=3). E. Quantification of apoptotic responses in indicated CRC cells upon shURI1(2)-mediated URI1 depletion. Green and red denote 
URI1-dependent and -independent CRC cell lines, respectively. Error bars represent SD of three independent experiments taken from 
Supplementary Figure 1A. F. Achilles database: sensitivity of colorectal cancer cell lines to URI1 and PFDN1 shRNAs. PFDN1 #1 and #2 
denote the two significant shRNA sets identified by the ATARiS algorithm for PFDN1. Dotted lines represent a two-fold change.
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the R2TP complex important for the assembly of RNA 
polymerases and PI3K-related protein kinases [5, 11, 12]. 
To this end, we established a list of representative genes 
corresponding to each of these networks (Supplementary 
Table S3). Among these selected genes, those contained 
in the Achilles database were used to compute the 
correlation in sensitivity with respect to URI1 across 20 
CRC cell lines but, following adjustment for multiple 
hypothesis testing, none reached statistical significance 
(Supplementary Figure S1D). We note however a trend 
that the sensitivity of CRC cell lines to shRNAs targeting 
the PI3K-mTORC-S6K axis is inversely correlated to 
URI1 sensitivity (Supplementary Figure S1D). Finally, 
we explored whether known frequent genomic alterations 
in CRC correlate with URI1 sensitivity. By taking the 
8 most frequently mutated genes in CRC (derived from 
The Cancer Genome Atlas Network [24]), we performed 
a computational analysis and found that, of these, KRAS, 
TP53, and FBXW7 displayed the largest differences in 
mutation frequency between URI1-sensitive and URI1-
insensitive cell lines (Supplementary Figure S1E). Neither 
of these differences were statistically significant after 
adjustments for multiple hypothesis testing (Fisher exact 
test with pFDR correction). Interestingly however, KRAS 
mutations, when restricted to the G12 or G13 positions, 
were found in 7 out 9 URI1-insensitive CRC cell lines but 
only in 2 out of 12 URI1-sensitive cell lines (pFDR value 
of 0.0644). This result may possibly imply that URI1 
sensitivity is dependent on KRAS status in CRCs.
URI1-dependent CRC cell lines are also 
dependent on the α-class PFD STAP1
Next we explored whether URI1’s requirement for 
cell survival of a subset of CRC cell lines relates to its role 
as a component of the ‘prefoldin-like’ URI1C. To assess 
this, we also depleted URI1’s direct α-PFD binding partner 
STAP1 with two specific shRNAs [shSTAP1(1) and 
shSTAP1(2)] in CRC cells (Supplementary Figure S2A). 
As exemplified in Figure 2A, only the URI1-dependent 
cell line RKO(mut), but not the URI1-independent cell line 
Lovo, underwent cell death upon STAP1-depletion and 
also failed in colony formation (Figure 2B). Furthermore, 
across the panel of 14 CRC cell lines, cell death provoked 
by STAP1 depletion with two distinct shRNAs mirrored 
that of URI1 depletion (Figure 2C and 2D, Supplementary 
Figure S2B and S2C). At the biochemical level, depletion 
of STAP1 was paralled by loss of endogenous URI1 
protein and vice versa (Figure 2E), suggesting that STAP1 
and URI1 are reciprocally required for each other’s protein 
expression. In line with this observation, the extent of 
cell death in RKO(mut) cells observed upon combined 
depletion of URI1 and STAP1 was similar to the extent of 
cell death observed upon depletion of URI1 alone (Figure 
2F). That URI1 and STAP1 act as part of the URI1C to 
mediate survival of a subset of CRC cell lines suggests that 
certain cancer cells have evolved a specific dependency on 
this class of molecular chaperone complexes.
URI1 suppresses p53 activation in URI1-
dependent CRC cells
Among frequent genetic alterations interfering 
with apoptosis in human cancers including CRCs are 
mutations in the p53 tumor suppressor [24]. p53 is 
activated in response to a broad range of extrinsic and 
cell intrinsic stress signals to halt cell cycle progression 
and induce cell death [25]. Hence, we tested whether p53 
is differentially activated in URI1-dependent RKO(mut) 
and VACO(wt) and URI1-independent Co115 and Lovo 
cells. These four cell lines are known to express wild-type 
p53. The functionality of the p53 pathway in these cells 
was experimentally confirmed by treatment with the DNA 
damaging agent etoposide. As shown in Supplementary 
Figure S3A, etoposide induced p53 protein expression in 
p53 wildtype CRC cells and concommitantly, known p53 
target genes including PUMA, NOXA and CDKN1A were 
activated. No such response was seen in two p53-defective 
cell lines HT29 and LS411N [26] (Supplementary Figure 
S3A) (http://www.broadinstitute.org/ccle/home).
Depletion of URI1 in the four p53 wildtype CRC cell 
lines mentioned above resulted in a profound accumulation 
of p53 in URI1-dependent but not -independent cell 
lines (Figure 3A and 3B). This effect and the associated 
apoptosis were both abolished by concurrent lentivirus-
mediated re-expression of a URI1 cDNA harboring silent 
mutations (referred to as URI1CO) that enable escape 
from URI1-targeting shRNAs (Figure 3C). Moreover, 
URI1 depletion-induced p53 accumulation was the 
result of an increase in p53 protein stability as evidenced 
by cycloheximide-chase experiments (Supplementary 
Figure S3B). Importantly, in those CRC cells, in which 
URI1 depletion caused p53 activation, it also induced 
cell death in a p53-dependent manner as evidenced by the 
fact that the simultaneous downregulation of URI1 and 
p53 suppressed, to a significant extent, albeit not fully, 
cell death (Figure 3D and 3E). Similarly, we observed 
in these samples also induction of p21, downregulation 
of MDM2 and activation of p53 target genes, responses 
that were abolished by the simultaneous depletion of 
p53 (Figure 3D and 3E, Supplementary Figure S3C). 
Hence, p53 activation and p53-dependent cell death are 
specific consequences of impaired URI1 function in URI1-
dependent CRC cell lines.
Activation of p53 through disrupted URI1 
function precedes DNA damage
To examine whether p53 activation is a consequence 
of URI1 depletion-induced DNA damage or not, we 
assessed phosphorylation of histone H2AX at S139 
(referred to as γH2AX), a well-established read-out 
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Figure 2: URI1-dependent CRC cells are also dependent on the α-class PFD STAP1. A. Representative apoptosis 
measurements of indicated CRC cells by Annexin V-GFP and propidium iodide double-staining after targeting STAP1 with two different 
shRNAs or control shRNA (n=3). B. Representative clonogenic assays of cells described in (A) (n=3). C. Quantification of apoptotic 
responses in indicated CRC cells upon shSTAP1(1)-mediated STAP1 depletion. Apoptosis increase relative to shCtrl following shRNA-
mediated STAP1-depletion is displayed. Data are means of three biological replicates taken from Supplementary Figure S2B, ± SD. D. 
Relative levels of apoptosis induced by URI1 or STAP1 depletion in a panel of 14 CRC cell lines. Each cell line is represented by a pair of 
data points reflecting the two shRNAs used against each gene. E. Immunoblots for indicated proteins after expression of shRNAs targeting 
URI1, STAP1 or both. F. Apoptotic response measurements by Annexin V-GFP/PI co-staining in cells corresponding to E. Data are shown 
as means of three biological replicates, ± SD.
Oncotarget29640www.impactjournals.com/oncotarget
for DNA double-strand breaks [27], in RKO(mut) and 
VACO(wt) cells, in which URI1 was downregulated in a 
doxycycline-dependent manner. URI1 depletion caused 
strong induction of γH2AX (Figure 4A and 4B). This 
response was blocked by simultaneous treatment of these 
cells with the pan-caspase apoptosis inhibitor zVAD-
FMK, but p53 protein remained induced (Figure 4A and 
4B). As shown in Supplementary Figure S4, doxycyclin-
induced downregulation of URI1 was accompanied by 
p53-dependent activation of the p53 target genes NOXA, 
PUMA, CDKN1A and MDM2. These observations indicate 
that the induction of γH2AX and apoptosis occur likely as 
a result of p53 activation and not through interference with 
URI1 function leading to a p53 stabilization secondary to 
apoptotic DNA damage.
To further corroborate this, we followed p53, p21 
and γH2AX expression and corresponding extent of cell 
death in RKO(mut) cells over time. As shown in Figure 
4C, as URI1 protein became depleted, p53 and p21 
accumulated. Only at later time points, levels of γH2AX 
started to rise coinciding with the induction of cell death. 
These results demonstrate that in a subset of CRCs, URI1 
loss promotes a cell death response that is mediated by 
and dependent on p53. URI1-independent CRC cell lines 
expressing wildtype p53 fail to execute such a response. 
In addition, the accumulation of γH2AX appears to be the 
result of DNA fragmentation that occurs during apoptosis 
and is therefore subsequent to URI1 loss-of-function-
induced p53 activation in URI1-dependent CRC cells. 
Together, these data support a model, in which a root cause 
Figure 3: URI1 depletion causes activation of p53 in URI1-dependent CRC cells. A, B. Immunoblots for indicated proteins 
upon URI1-depletion in URI1-dependent VACO(wt) and RKO(mut), and URI1-independent Co115 and Lovo cells, respectively. (n=3) C. 
Immunoblotting and measurement of apoptosis in VACO(wt) cells upon shURI1(2)-mediated URI1-depletion, with or without simultaneous 
re-expression of URI1 protein from a plasmid containing a URI1-codon optimized (URI1CO ) coding sequence. (apoptosis assay n=3) D, E. 
Assessment of apoptosis levels and immunoblots for indicated proteins of URI1-depleted RKO(mut) and VACO(wt) cells, with or without 
concomitant p53-kd. Data are means of three biological replicates, ± SD.
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of differential p53-dependent apoptosis induction in CRC 
cells may be related to the disruption of URI1C-regulated 
client protein assembly/folding pathways.
URI1-dependent CRCs require URI1 function 
for tumor growth in vivo
Given the importance of URI1 function for the 
survival of a subset of CRC cells in vitro, we asked 
whether this dependency also extends to an in vivo setting. 
To this end, we injected equal numbers of RKO(mut).
teton.shURI1(2) or -shCtrl cells into the right and left 
flanks of immunocompromised Balb/c-nude mice, 
respectively. After successful engraftment when the 
tumor reached a certain size, one half of the mice received 
doxycycline (dox)-containing food. As illustrated in 
Figure 5A and 5B, RKO(mut).teton.shURI1(2) tumors 
displayed massively reduced tumor growth compared to 
shCtrl tumors or to tumors grown in mice on normal chow. 
Dox treatment did not affect the weight of mice over the 
time course of the experiment (Supplementary Figure S5). 
Explanted RKO(mut).teton.shURI1(2) tumors from dox-
treated mice were on average much smaller than any of 
the control tumors (Figure 5B and 5C). Extraction of total 
RNA from four explanted tumors per group followed by 
qPCR analysis revealed reduced mRNA levels of URI1 
in URI1-depleted tumors compared to control tumors 
and increased expression of the p53 target gene NOXA 
in the corresponding samples (Figure 5D). Thus, URI1 
function is required for maintenance of tumor growth and 
the suppression of the p53 target gene NOXA in URI1-
dependent CRC cells in vivo.
DISCUSSION
In this study we established the following 
experimental points. The unconventional PFD chaperone 
URI1 is selectively required for survival of a subset of 
CRC cell lines. Underlying this phenomenon is a property 
of URI1 to mediate cell survival, at least in part, through 
suppression of non-genotoxic activation of p53-dependent 
apoptosis both in vitro and in tumor xenografts. URI1-
independent CRC cells do not activate p53-dependent 
Figure 4: URI1 depletion-induced apoptosis causes γH2AX accumulation. A, B. p53 activation and γH2AX accumulation 
upon URI1-depletion, in combination with blockade of apoptosis using 100µM of the pan-caspase inhibitor zVAD-FMK 
(or DMSO as vehicle control) in both RKO(mut) (A) and VACO(wt) (B) cells. (n=3) C. Immunoblots for URI1, p53, p21, 
γH2AX and ERK1/2 following URI1 depletion in RKO(mut) cells using a dox-inducible shURI1(2) construct (left), and the 
corresponding apoptosis levels (right). Data are shown as means of three biological replicates, ± SD.
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Figure 5: URI1 is required for tumor growth of URI1-dependent CRC cells after tumor establishment. A. Mean tumor 
volume measurements of mice xenografted in both flanks with RKO(mut) cell line pools containing dox-inducible shURI1(2), as indicated. 
The arrow marks the start of feeding dox-containing chow to mice. n=8-10 flanks per group, error bars represent ± SEM, ***P ≤ 0.001. 
B. Mean tumor mass of explanted tumors, ± SEM, **P = 0.0025 C. A corresponding representative set of pictures of mice. D. qPCR analysis 
of tumors to assess URI1-kd efficiency and induction of the p53 target gene NOXA, n=4 tumors per group, mean values ± SD, ****P < 
0.0001, **P = 0.0013. Values are normalized to geometric mean (geNorm) of TBP and 18S and shURI1(2) –dox (arbitrarily set as 1.0).
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apoptosis when URI1 function is compromised indicating 
that they have likely evolved a dependency on other 
cellular chaperone systems for their survival. The fact 
that STAP1-dependency of CRC cells parallels that of 
URI1 supports the view that this phenomenon is linked to 
URI1C and thus represents a relevant chaperone function. 
These findings suggest that URI1 has properties of a 
‘non-oncogene’ that supports the oncogenic phenotype 
of those cancer cells that have evolved a dependency 
on this molecular chaperone system for survival. Thus, 
depending on the cancer cell context, URI1 can mediate 
‘oncogene addiction’ as is the case in carcinomas with 
URI1 copy number increase [20] or ‘non-oncogene 
addiction’ as in CRCs, marking URI1 and the URI1C 
attractive targets to be exploited for cancer therapy.
The very same CRC cell lines that rely on URI1 
function for their survival, rely also on STAP1 for their 
viability. That depletion of URI1 caused concomitant 
loss of endogenous STAP1 and vice versa provides a 
biochemical explanation for the above-noted observation. 
It is also in line with the observation that the extent of 
apoptosis following depletion of either URI1 or STAP1 
alone is similar to the levels of apoptosis seen after 
combined depletion of both α-PFD subunits. Deletion of 
single components from the classical prefoldin-/GimC-
complex has been shown to cause degradation of the 
remaining subunits via a ubiquitin-proteasome pathway 
[28]. Thus, it is conceivable that the observed phenotypes 
associated with URI1 (and STAP1) depletion shown here 
are the result of impaired URI1C function and consequent 
client protein misbehaviour.
The URI1C engages with multiple client proteins 
to execute cell regulatory functions [3]. This provides a 
significant challenge for pinpointing precise mechanisms, 
through which silencing of URI1 leads to the activation 
of p53 and p53-dependent apoptosis in URI1-dependent 
CRC cell lines. However, URI1C has been shown to 
associate with R2TP (Rvb1/2, Tah1, Pih1) and HSP90, 
which together form a larger complex important for the 
assembly and stability of phosphatidylinositol 3-kinase-
related kinases (PIKKs), in particular mTOR and SMG1 
[12, 29, 30]. Moreover, URI1C has also been demonstrated 
to mediate the assembly of all three RNA polymerases, a 
function dependent on RPB5, a direct binding partner of 
URI1 and common subunit of RNA pol I, II and III [5, 11, 
14, 31]]. Of note, there is ample evidence linking impaired 
function of either one of the three RNA polymerases to 
p53 activation and apoptosis [32-34]. Hence, the combined 
misbehaviour of these various URI1C clients may, in the 
aggregate, contribute to the observed non-genotoxic p53 
activation and p53-dependent apoptosis. Accordingly, 
in URI1-independent CRC cells, even in the setting 
of wildtype p53 expression, other chaperone systems 
may functionally substitute for the URI1C. Functional 
compensation through other chaperones has been observed 
in the case of HSP72 that can substitute for HSC70 in the 
context of HSP90 function [35].
Finally, emerging evidence suggests that tumor 
cells have evolved dependencies on specific molecular 
chaperone systems that protect them from proteotoxic 
stress and alongside provide specific vulnerabilities 
that can be exploited for anti-cancer therapy [1]. This 
is particularly well illustrated by work on members 
of the heat-shock protein (HSP) family. Increased 
expression of HSP90, for example, is a common feature 
of many cancers where it plays a key role in ensuring 
the proper folding, stability and activity of many client 
proteins. Drugs that block HSP90 ATPase activity 
such as 17-allykl-amino-17-demethoxygeldanamycin 
demonstrate potent anti-tumor activity due to, in part, 
drug-induced degradation of many cancer promoting 
HSP90-client proteins and the concurrent inhibition 
of multiple cancer-promoting signaling pathways [2]. 
The work presented here suggests that certain cancer 
cells have also evolved a dependency on a molecular 
chaperone system important for de novo protein folding 
for their survival. Thus, targeting specific interactions 
within the URI1C may provide an attractive therapeutic 
opportunity.
MATERIALS AND METHODS
Cell lines and culture
The following colon cancer cell lines and culture 
media were used: RKO, VACO432 and HCT116 (B. 
Vogelstein, John’s Hopkins University) and HT29 
(Zurich Cancer Network’s Cell Line Repository) were 
cultured in DMEM; LS411N, HCT15, Co115, Colo205 
and KM12 (Zurich Cancer Network’s Cell Line 
Repository) were cultured in RPMI; HT55 (ECACC) 
was cultured in DMEM-20; SW620 (Zurich Cancer 
Network’s Cell Line Repository) was cultured in Leibo; 
Lovo (Zurich Cancer Network’s Cell Line Repository) 
was cultured in F12. 293T embyronic kidney cells 
(ATCC) were cultured in DMEM. Cells from the Zurich 
Cancer Network’s Cell Line Repository have undergone 
only a few passages since purchase from ATCC and 
are certified to be free from mycoplasma infection. 
DMEM = DMEM, high Glucose, NEAA (Gibco), 
supplemented with 2 mM L-Glutamine (Gibco) and 
10% FCS (Ambimed). RPMI = RPMI 1640 + GlutaMax 
(Gibco), supplemented with 10% FCS (Ambimed). 
DMEM-20 = DMEM, high Glucose, NEAA (Gibco), 
supplemented with 2 mM L-Glutamine (Gibco) and 20% 
FCS (Ambimed). Leibo = Leibovitz’s L-15 + GlutaMax 
(Gibco), supplemented with 10% FCS (Ambimed). F12 
= DMEM/F12 + GlutaMax (Gibco), supplemented with 
10% FCS (Ambimed). Cells were maintained at 37 °C in 
a humidified atmosphere with 5% CO2.
Oncotarget29644www.impactjournals.com/oncotarget
Colony formation assay
Cells were seeded in 6-well plates (Greiner) with 
10’000 cells/well and cultured for 7 to 10 days until 
approximately 50 to 70% of the surface was covered in the 
wells with the highest confluence. Cells were then fixed 
and stained using crystal violet staining solution (0.5% 
w/v crystal violet, 70% methanol), washed using ddH2O 
and dried prior to scanning and quantification using the 
ImageJ software.
Transfections
For transient transfection of siRNAs, 
Lipofectamine® RNAiMAX (Invitrogen) was used 
according to the manufacturer’s instruction. URI1(1) 
(AACUUGUCCAUACUAAUGAAG) and URI1(2) 
(AAGGUAUCCUGAGUUACUUUG) siRNA sequences 
were as described previously [16]. sip53(1) and (2) 
sequences were AAGGAAAUUUGCGUGUGGAGU and 
UUGGUGAACCUUAGUACCUAA, respectively. The 
AllStars Negative Control siRNA from Qiagen was used as 
a non-targeting siRNA control. For plasmid transfections 
(to generate lentiviruses, see below), X-tremeGENE 9 
DNA Transfection Reagent (Roche) was used according 
to the manufacturer’s instruction.
Generation and application of lentiviruses
For stable shRNA-mediated knockdown, pLKO-1 
vectors from Sigma were purchased and lentiviral particles 
produced by co-transfection of the shRNA-containing 
vectors with 2nd generation packing plasmids psPAX2 and 
pMD2G (Addgene clones 12260 and 12259, respectively) 
into 293T/17 cells. Virus was harvested after 48 hrs, 
filtered, and polybrene added to a final concentration of 8 
µg/ml. Viral supernatants were used to infect target cells 
for 48 hrs and pools selected using 2 to 4 µg/ml puromycin, 
for 2 to 4 days. URI1 shRNA(1) and shRNA(2) were also 
subcloned into a blasticidin-containing pLKO-1 vector and 
pools selected using 10 to 20 µg/ml blasticidin for 4 to 6 
days. For double knockdown, rescue or complementation 
experiments, double selection using both puromycin 
and blasticidin was employed. For URI1-kd, clones 
TRCN0000074239 = shURI1(1) and TRCN0000074242 
= shURI1(2) were used. For p53-kd, TRCN0000010814 
= shp53(1) and TRCN0000003755 = shp53(2), and 
for STAP1-kd, TRCN0000154852 = shSTAP1(1) and 
TRCN0000157240 = shSTAP1(2) were used. As control, 
pLKO-1 vectors (puromycin and blasticidin) containing 
a scrambled control shRNA were used. URI1 shRNA(2) 
was also sub-cloned into a doxycycline-inducible pLKO-1 
vector [pLKO1.teton.shCtrl or -shURI1(2)], as described 
[36]. Doxycycline was purchased from Sigma Aldrich. For 
experiments using the pLKO1.teton system, tetracycline-
free FCS was used and doxycycline-containing medium 
was replaced every 48 hrs.
For stable over-expression and kd-rescue 
experiments, a codon-optimized URI1 transcript (URI1co), 
which escapes RNAi, was cloned into a CMV-containing 
pLKO-1 vector (pLKO1-CMV::URI1CO). The construct 
differed in the shRNA-binding sequences as follows 
(spaces mark codons, silently mutated bases are shown 
underlined): shURI1(1)’s target sequence C TTG CCT 
GAT AAA TTG TCT T was mutated to A CTG CCC GAC 
AAA CTG TCA T, and shURI1(2)’s target sequence CT 
AAG AGG GTC CGA ATA AAT was mutated to CA AAG 
CGA GTC AGG ATT AAC in URI1CO.
Annexin V and propidium iodide stainings
Cells harvested by trypsinization were washed with 
Annexin V binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 
mM NaCl and 2.5 mM CaCl2) and incubated with His-GFP-
Annexin V-containing Annexin V binding buffer, as described 
previously [37]. Propidium Iodide (PI) was added just prior 
to assessing apoptosis by flow cytometry. Stained cells were 
analyzed using a BD FACSCalibur™ or BD Accuri™ C6 and 
the obtained data was analyzed with the FloJo software.
Immunoblotting and antibodies
Immunoblotting was performed as described previously, 
on nitrocellulose membranes using a trans-blot turbo blotting 
device (Bio-Rad) [16]. Alternatively, 4-20% Mini-PROTEAN 
TGX Stain-Free Gels and Trans-Blot Turbo Transfer Packs 
(PVDF) were used, according to the manufacturer’s protocols 
using a trans-blot turbo blotting device (Bio-Rad). The URI1 
(mAb 58.1) and STAP1/UXT (mAb 105.128) antibodies have 
been described previously [5]. ERK1/2 (#9101) and P-Histone 
H2A.X S139 (abbreviated as γH2AX, #9718) antibodies 
were purchased from Cell Signaling Technology. MDM2 (sc-
812) and p21 (sc-397-G) were purchased from Santa Cruz 
Biotechnology, β-actin (A5316) from Sigma Aldrich, and p53 
(14211A) from BD Pharmingen.
Chemicals
To inhibit apoptosis, the pan-caspase inhibitor 
zVAD-FMK (MBL International) was used. In long-
term experiments, zVAD-FMK containing medium 
was exchanged every 48 hrs. The proteasomal inhibitor 
MG132 was purchased from Biomol. Cycloheximide 
(CHX) was obtained from Sigma-Aldrich.
Quantitative real-time RT-PCR (qPCR)
Samples from cultured cells and explanted 
xenografts were processed using the RNA II kit 
(Macherey-Nagel) according to the manufacturer’s 
protocol. 1 to 5 µg total RNA were transcribed 
using the RNA to cDNA EcoDry Premix (Random 
Hexamers) kit (Clontech). qPCRs were run on a Roche 
LightCycler LC480, using the following program: 5 
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min pre-incubation at 95°C, 40 amplification cycles 
(10 sec 95°C, 10 sec 60°C, 10 sec 72°C) and melting 
curve. Obtained data was analyzed using the Biogazelle 
qbase+ software. Employed PCR primers were: 
HPRT1 (forward: CCTGGCGTCGTGATTAGTGAT; 
reverse: AGACGTTCAGTCCTGTCCATAA); ACTB 
(forward: CCTCGCCTTTGCCGATCCG; reverse: CCACC 
ATCACGCCCTGGTG); GAPDH (forward: GAAGGTG 
AAGTTCGGAGTC; reverse: GAAGATGGTGATGGG 
ATTTC); RNA18S5 (forward: GTTCCGACCATAAAC 
GATGC; reverse: TGGTGGTGCCCTTCCGTCAAT); 
TBP (forward: TTCGGAGAGTTCTGGGATTGT; reverse: 
TGGACTGTTCTTCACTCTTGG C); HMBS (forward: 
ATGTCTGGTAACGGCAATGC; reverse: CGTCTGTAT 
GCGAGCAAGC); URI1 (forward: AATGCCCTTCGA 
GAAAGACTCA; reverse: CCCCCAGTAAAACAGTG 
ACTTC); BBC3/Puma (forward: GACCTCAACGCAC 
AGTACGAG; reverse: AGGAGTCCCATGATGAGAT 
TGT); PMAIP1/Noxa (forward: GCAAGAACGCTCAA 
CCGAG; reverse: AAGTTTCTGCCGGAAGTTCA); 
CDKN1A (forward: AGTCAGTTCCTTGTGGAGCC; 
reverse: CATGGGTTCTGACGGACAT); MDM2 
(forward: TGTTGTGAAAGAAGCAGTAGCA; reverse: 
CCTGATCCAACCAATCACCT).
Xenograft experiments
For xenograft experiments, six weeks old female 
BALB/cAnNRj-Foxn1nu/nu mice were purchased from 
Janvier. After two weeks of adaption to the mouse 
facility, 2 x106 RKOmut.to.shCtrl or –shURI1(2) cells 
resuspended in PBS v/v 50% phenol-red free matrigel (BD 
Biosciences) were injected into the left and right flanks 
of 20 mice, respectively. After successful engraftment (8 
days), mice were randomized to two groups and fed with 
chow containing 200 mg/kg doxycycline (doxycycline 
from Sigma-Aldrich; chow was produced and sterilized 
by Provimi-Kliba) and control chow, respectively. Mice 
were clinically observed and tumor sizes measured 
by caliper every two days. Tumor volumes were 
calculated as follows: vol = D * d2/2 with D being the 
greatest longitudinal diameter of the tumors, and d 
being the greatest transverse diameter [38]. At the end 
of the experiment, mice were sacrificed and the tumors 
explanted, weighed and snap frozen for extraction of total 
RNA (see section on qPCR).
Mean xenograft tumor volumes were analyzed by 
two-way RM ANOVA and Tukey correction for multiple 
testing, and means of body weights of mice were analyzed 
by two-way RM ANOVA. qPCR data of explanted 
xenograft tumors (n=4) were analyzed by ordinary one-
way ANOVA and Dunnett’s multiple comparisons test. 
Explanted tumor weights were analyzed by Kruskal-Wallis 
and Dunn’s multiple comparisons test.
All animal work was performed in accordance with 
the guidelines of the institutional animal care and local 
veterinary office and ethics committee of the Kanton 
Zurich, Switzerland (reference number 149/2011) under 
approved protocols.
Data presentation and analysis
All statistical analyses and data presentation were 
generated using the Prism 6 software (GraphPad Software 
Inc.) and R 3.2.3. Test details are given in the respective 
subsections (see below).
Achilles analysis
Cell lines sensibility to shRNAs for URI1 and 
other genes as indicated were taken from the Achilles 
database v2.4 [23]. Values are ATARiS gene level scores 
(i.e. the average fold-change of shRNAs with consistent 
values across the 216 cell lines). Correlation between 
two genes was computed as the Pearson correlation. A 
pFDR correction for multiple hypothesis was applied 
when needed. URI1-sensitive cells were defined as cell 
lines with a log2 shRNA fold-change value below zero. 
Mutation status for the Achilles cell lines was taken from 
the Broad-Novartis Cancer Cell Line Encyclopedia (http://
www.broadinstitute.org/ccle).
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